Azimuth Capital Investment Management LLC Sells 59,266 Shares of DexCom, Inc. (NASDAQ:DXCM)

Azimuth Capital Investment Management LLC trimmed its position in DexCom, Inc. (NASDAQ:DXCMFree Report) by 30.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 136,800 shares of the medical device company’s stock after selling 59,266 shares during the period. Azimuth Capital Investment Management LLC’s holdings in DexCom were worth $16,976,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. DSM Capital Partners LLC bought a new stake in DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. raised its stake in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. boosted its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the last quarter. Smithfield Trust Co grew its stake in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Finally, Washington Trust Advisors Inc. increased its holdings in DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after buying an additional 193 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the transaction, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the sale, the executive vice president now owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 187,293 shares of company stock worth $25,295,452. Company insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM traded up $0.49 on Friday, reaching $115.79. The stock had a trading volume of 3,009,534 shares, compared to its average volume of 2,637,164. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $46.05 billion, a price-to-earnings ratio of 74.70, a price-to-earnings-growth ratio of 2.82 and a beta of 1.22. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The firm has a 50-day moving average of $129.67 and a 200-day moving average of $125.66.

DexCom (NASDAQ:DXCMGet Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DXCM. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective for the company. Canaccord Genuity Group upped their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Raymond James raised their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Redburn Atlantic began coverage on DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price on the stock. Finally, StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a report on Sunday, June 2nd. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $140.94.

Check Out Our Latest Report on DexCom

About DexCom

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.